Drug Trial Radar · NCT01765881
Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2
Last checked: Nov 20, 2026Latest source record: Apr 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,700
Actual
Start
Sep 2012
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For about 10% of pregnancies, it is necessary to induce delivery for medical reasons. Prostaglandins alone can be used to perform cervical ripening in cases of immature cervix. In France, dinoprostone is the own approved medication. It is in the form of gel or sustained release device whose effectiveness and side effects are comparable. The vaginal misoprostol has no marketing authorization in France, but is sometimes used. Some data in the scientific literature have showed that its use with low-dose (25 mcg) vaginally did not lead to more complications, was at least as effective and seems to be cost-effective compared with dinoprostone. Misoprostol with this dose and route of administration is now recommended by the American College of Obstetricians and Gynecologist (ACOG), Grade A (ACOG Practice Bulletin August 2009). This is not the case in France (French HAS 2008 Guidelines on induction of labor). According to HAS, the investigators still lack data on large samples to confirm the benefits of misoprostol 25 mcg vaginally, in terms of efficiency, rate of cesarean section, and lower cost compared to dinoprostone. The primary objective is to demonstrate non-inferiority of vaginal misoprostol 25 mcg vs. dinoprostone in terms of cesarian section occurence with a non-inferiority margin of +5% difference.
Conditions
- Delivery Uterine
Interventions
MisoprostolDrug
administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
DinoprostoneDrug
administration of one sustained released pessary of 10 milligrams by intravaginal route
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cesarean for all indicationsTime frame: Up to delivery
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Bicêtre Hospital
Le Kremlin-Bicêtre, France
Hospital Poissy
Poissy, France
Hôpitaux Universitaires de Strasbourg
Strasbourg, France
University Hospital Toulouse
Toulouse, France, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.